ABSCI CORP (ABSI) Stock Price, Forecast & Analysis
NASDAQ:ABSI • US00091E1091
ABSI Key Statistics, Chart & Performance
The current stock price of ABSI is 2.78 USD. In the past month the price decreased by -7.95%. In the past year, price decreased by -43.95%.
ABSI Technical Analysis
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. ABSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 3.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.78% | ||
| ROE | -54.49% | ||
| Debt/Equity | 0 |
ABSI Forecast & Estimates
15 analysts have analysed ABSI and the average price target is 8.21 USD. This implies a price increase of 195.2% is expected in the next year compared to the current price of 2.78.
For the next year, analysts expect an EPS growth of 8.18% and a revenue growth -18.65% for ABSI
ABSI Ownership
ABSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 156
Phone: 13026587581
ABSCI CORP / ABSI FAQ
What does ABSCI CORP do?
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Can you provide the latest stock price for ABSCI CORP?
The current stock price of ABSI is 2.78 USD. The price increased by 2.96% in the last trading session.
Does ABSCI CORP pay dividends?
ABSI does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABSI stock?
ABSI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for ABSCI CORP?
ABSCI CORP (ABSI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for ABSCI CORP?
The Revenue of ABSCI CORP (ABSI) is expected to decline by -18.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.